Roundhill GLP-1 & Weight Loss ETF
OZEMDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 31, 2025 | $0.41 | 2025-12-30 | 2025-12-30 |
| December 31, 2024 | $0.05 | 2024-12-30 | 2024-12-30 |
Dividends Summary
- Consistent Payer: Roundhill GLP-1 & Weight Loss ETF has rewarded shareholders with 2 dividend payments over the past 1 years.
- Total Returned Value: Investors who held OZEM shares during this period received a total of $0.46 per share in dividend income.
- Latest Payout: The most recent dividend of $0.41/share was paid 23 days ago, on December 31, 2025.
- Yield & Schedule: OZEM currently pays dividends yearly with an annual yield of 1.11%.
- Dividend Growth: Since 2024, the dividend payout has grown by 672.4%, from $0.05 to $0.41.
Company News
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential. The Roundhill GLP...
The market for GLP-1 drugs could soar to $130 billion by 2030
The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning weight-loss drug market, making up over 40% of OZEM’...
Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceutica...
